Reports › Company profiles › Dabur India Limited
Dabur India Limited
Sector: FMCG (Ayurveda, Personal Care, Foods, Healthcare) | HQ: Ghaziabad, Uttar Pradesh | Founded: 1884 | Employees: ~7,500
Listed as: NSE / BSE listed; Nifty 50 constituent | NSE / BSE | Ticker: DABUR.NS | Website →
Live stock price (NSE)
₹473
-14.25 (-2.92%) today
Source: Yahoo Finance · Refreshed every 15 minutes · Fetched 11/5/2026, 4:34:40 pm IST. For information only; not investment advice.
Key people
- Mohit Burman (Chairman)
- Mohit Malhotra (CEO)
Company overview
Dabur India Limited is one of India's oldest FMCG companies and the world's largest Ayurvedic and natural products company. Founded in 1884 by Dr S K Burman in Kolkata, Dabur is now headquartered in Ghaziabad and operates 21 manufacturing facilities globally (13 in India). FY25 consolidated revenue was approximately ₹12,500 crore. Iconic brands include Dabur Chyawanprash, Dabur Honey, Dabur Hajmola, Dabur Red Toothpaste, Dabur Amla, Vatika, Real Juice, Hommade, and the recently acquired Badshah Masala portfolio.
Business model
Dabur operates four reporting segments. Consumer Care (Healthcare, Personal Care, Foods) is the largest. International Business covers Middle East, Africa, US, UK exports. Foods grew through Real Juice acquisition and Badshah Masala acquisition. Healthcare covers Ayurvedic OTC and prescription products.
Operating segments
Healthcare (OTC)
Chyawanprash, Honey, Hajmola, Lal Tail. India's leading Ayurvedic OTC franchise.
Home and Personal Care
Dabur Red Toothpaste, Meswak, Babool, Dabur Amla, Vatika hair care, Odonil air freshener.
Foods (Real, Hommade)
Real Juice (India's leading branded juice), Hommade ready-to-cook, Badshah Masala.
International
Middle East, Africa, USA, UK distribution and manufacturing.
Financial performance and recent trajectory
Dabur reported FY25 revenue of ₹12,500 crore with EBITDA margin of approximately 19 percent. The Badshah Masala acquisition (₹588 crore) added to the foods portfolio. International business contributes approximately 22 percent of revenue.
Stock performance and shareholder context
Dabur (NSE: DABUR, BSE: 500096) is Nifty 50 constituent. Burman family trust holds approximately 67 percent.
12-month price trajectory
Monthly closes over the last 12 months. Source: Yahoo Finance.
Competitive position
Dabur leads Indian Ayurvedic FMCG ahead of Patanjali, Himalaya, and Emami in the natural-products segment.
Key risks
Slowing rural FMCG demand; competitive intensity from Patanjali and HUL Ayush range; juices category competition from PepsiCo Tropicana and Coca-Cola Minute Maid.
Outlook
Strong outlook on the secular growth of Ayurvedic FMCG and the rural India FMCG penetration trajectory.
KAMRIT point of view
Building or competing with Dabur?
KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the fmcg (ayurveda sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Dabur and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.
Related KAMRIT project reports
These reports use Dabur India Limited in benchmarking and competitive analysis sections.
Ayurveda & Herbal Products Plant Project Report
Manufacturing · Market ₹95,000 crore · CAGR 15.2%
Honey Processing & Bottling Project Report
Food & Beverage Processing · Market ₹2,800 crore · CAGR 11.5%
Spices Processing & Packaging Plant Project Report
Food & Beverage Processing · Market ₹70,000 crore · CAGR 10.1%
Nutraceuticals & Wellness Plant Project Report
Pharma & Healthcare · Market ₹38,000 crore · CAGR 17.4%
Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.